Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.
about
The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatmentsStress and visceral pain: from animal models to clinical therapiesNovel therapeutic agents in neurogastroenterology: advances in the past year.Review article: new receptor targets for medical therapy in irritable bowel syndromeTachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?Novel therapeutic approaches in IBS.The enteric nervous system: normal functions and enteric neuropathies.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.Current and novel therapeutic options for irritable bowel syndrome management.Tachykinin receptor antagonists in clinical trials.Investigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia.Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.Electrophysiological characterization of human rectal afferentsEffects and mechanisms of gastric electrical stimulation on visceral pain in a rodent model of gastric hyperalgesia secondary to chemically induced mucosal ulceration.
P2860
Q26739291-4366A8A5-421C-46F5-BC2B-E63A5C24C496Q30459512-ACD83F3C-2EC0-4FBE-85A5-094A01B81BBFQ33934623-BCB82F10-04B1-4B13-B853-F6DB0C10C5F9Q33959307-212B0DA9-EB9E-405C-84C0-4985255B840DQ34171734-D1B1E2C6-59F4-4206-814C-E839505B56EBQ36023377-72D46A2D-44C1-46F1-8556-95CB74A4F478Q37002201-2D708F55-6B0E-4092-BA30-54D9A9AA6B35Q37134535-F8BE873D-D055-47CF-83B6-4ADE8080C210Q37164063-B8A035DC-3F5A-4BB8-ADD9-D08422FF9DCFQ37426287-77152ED9-32D6-404D-B3B0-AF87F4348223Q37438547-EAAA9B6E-7DC0-4BC5-B96E-2B8C5B912C7FQ37638682-6F3BEE59-8E6F-4C2B-8FD8-74EE6BCDA251Q37788218-CFFC5E87-0259-4B54-899A-33353E848571Q37857849-946FC3E5-DBCA-4593-9433-7DD55DE993DCQ37954521-CEA49BE0-F047-40D1-9860-E2195F389BC3Q38165173-521B8523-BE78-4E0E-B0D0-646DE7942345Q38531668-43F7F6C2-FA87-477A-90AA-F9237B9D8B71Q42323050-ACBFCFBA-08D5-486B-BCB6-0E6DD33B67A0Q47956242-2919655E-6E82-43B6-BB2F-C3C26C67A0F1
P2860
Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@ast
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@en
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@nl
type
label
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@ast
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@en
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@nl
prefLabel
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@ast
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@en
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@nl
P2093
P2860
P1476
Effect of the NK(3) receptor a ...... compliance in healthy humans.
@en
P2093
Busciglio I
Camilleri M
Cremonini F
Houghton LA
P2860
P304
P356
10.1111/J.1365-2982.2007.00934.X
P577
2007-09-01T00:00:00Z